Cancer - Prostate(구연) (E-142) 60세 이하 전이성 전립선암 환자의 임상적 결과 및 예후 분당서울대학교병원 비뇨의학과, 서울대학교 의과대학 비뇨의학교실 김환익, 예창희, 김정권, 이학민, 오종진, 이상철, 변석수, 홍성규 Objective: Metastatic prostate cancer (mPCa) rarely occurs under the age of 60, and the prognosis is reported to be worse than that of more than 60. There are few reports made, and scarce domestic data. We evaluated the clinical outcomes and prognosis of mPCa patients ≤ 60-year-old. Materials and Methods: Among the 2083 patients treated with mPCa from April 2003 to May 2020, 110 patients were identified. Based on the median age, 56-year-old, they were classified into Younger (≤56) group (n=58) and Young (57-60) group (n=52). Clinicopathological characteristics between groups, biochemical recurrence-free (BCR-free) survival, and overall survival were investigated. Results: The mean age was 52.2 years (Younger) and 58.5 years (Young), respectively (p<0.001) and the median follow-up period was 32 months (mo). The rates of metastasis at the time of diagnosis were 74.1% and 73.1% (p=0.900), respectively, and 41.4% and 48.1% (p=0.480) of each group received local treatment (Radical Prostatectomy or Radiation Therapy). Differences in clinical and pathological characteristics between groups were not significant except for hypertension (p=0.005). Median BCR-free Survival was significantly shorter in Younger group(14 mo vs. 40 mo, p=0.026), and the median overall survival was significantly different (87 mo for Younger group vs Not Reached for Young group, p=0.048) In multivariate analysis, factors related to BCR-free survival were local radical treatment (Hazard ratio(HR) = 0.39 [0.18-0.81], p=0.012). Significant predictors of overall survival are local radical treatment (HR = 0.11 [0.02-0.64], p=0.014) and Abiraterone use (HR = 18.45 [2.59-131.71], p=0.004). Conclusions: As patients gets younger in mPCa ≤ 60-year-old, BCR occurs earlier and OS is significantly reduced. Nevertheless, patients received local radical treatment (RP or RT) tend to have less BCR and longer OS. Therefore, special caution is mandatory when treating these mPCa patients. keywords : Metastatic Prostate Cancer, Age of 60 years and younger, Prognosis